Raplon / Rapacuronium

Modified on 2009/10/14 21:53 by admin
Raplon is an anesthetic manufactured by Organon, Inc. and approved by the Food and Drug Administration in August of 1999. Raplon is used to complement general anesthesia in order to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures.

On March 30, 2001 Organon announced that it was withdrawing Raplon from the market after several reports of severe adverse reactions in patients taking Raplon. Such side effects include, but may not be limited to, bronchospasm and death. Organon informed doctors to remove all packages of Raplon from their shelves immediately.

If you have experienced adverse side effects after receiving Raplon, it may be important to speak with your healthcare professional. Additionally, you may wish to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Anesthetics: Overview
  2. Bronchospasm: Overview
  Name Size